November 13, 2019 10:28 AM EST

Seattle and Daiichi Sankyo at each other's throats; UC Berkeley, UCSF and the University of Washington launch Weill Neurohub

ENDPOINTS

→ Seattle Genetics and Daiichi Sankyo — once partners — are now bitter foes battling over intellectual property underpinning ADC technology. After going their separate ways …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Seattle and Daiichi Sankyo at each other's throats; UC Berkeley, UCSF and the University of Washington launch Weill Neurohub

ENDPOINTS

Sign up to read this article for free.

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Halozyme withdraws Evotec acquisition proposal after biotech is 'unwilling to engage'

Are programs with compounded GLP-1s safe for your population?

Seat­tle and Dai­ichi Sankyo at each oth­er's throats; UC Berke­ley, UCSF and the Uni­ver­si­ty of Wash­ing­ton launch Weill Neu­ro­hub

ENDPOINTS

Sign up to read this article for free.

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Halozyme with­draws Evotec ac­qui­si­tion pro­pos­al af­ter biotech is 'un­will­ing to en­gage'

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Seattle and Daiichi Sankyo at each other's throats; UC Berkeley, UCSF and the University of Washington launch Weill Neurohub

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Halozyme withdraws Evotec acquisition proposal after biotech is 'unwilling to engage'

Are programs with compounded GLP-1s safe for your population?